NEW BRUNSWICK, NJ, 12 October 2021 / PRNewswire / – Johnson & Johnson (NYSE: JNJ) today announced the appointment of Jessica moore to the Vice President of Investor Relations of Johnson & Johnson, from November 1, 2021. Ms. Moore will report to Mr. Joseph wolk, Executive Vice-President and Chief Financial Officer of the Company.
Ms. Moore brings 20 years of strong, diverse and international financial experience spanning sales operations, corporate and regional positions. Most recently, Ms. Moore served as vice president and chief financial officer of Janssen’s pharmaceutical business in EMEA, where she played a critical role in financial performance analysis, risk assessment and risk assessment. opportunities and maintaining a strong and compliant environment. Prior to joining Johnson & Johnson, Ms. Moore held various leadership roles of increasing responsibility at Baxter International, where she focused on returning the EMEA business to growth and leading a transformation project to standardize and centralize financial processes in business and manufacturing entities.
âJessica’s knowledge of our business and industries positions her well to convey Johnson & Johnson’s strategies and results to the investment community and other key stakeholders,â said Mr. Wolk. “His dedication to innovative solutions and his commitment to talent development will have a positive impact on all aspects of our business.”
Ms. Moore holds a bachelor’s degree in finance and accounting from Miami (from Ohio) University and an MBA from the Kellogg School of Management at Northwestern University.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation for vibrant lives, thriving communities and progress. That’s why, for more than 130 years, we’ve strived to keep people healthy at all ages and at all stages of life. Today, as the world’s largest and most diverse healthcare company, we’re committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and make a healthy mind, body and environment available to everyone, everywhere. We combine our heart, our science and our ingenuity to profoundly change the trajectory of human health.
Note to Investors Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 concerning, among other things, future operational and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If the underlying assumptions prove to be incorrect or if known or unknown risks or uncertainties materialize, actual results could differ materially from Johnson & Johnson’s expectations and projections. Risks and uncertainties include, but are not limited to: risks related to the impact of the global COVID-19 pandemic, such as the extent and duration of the outbreak, government actions and restrictive measures implemented. work in response, significant delays and cancellations of medical procedures, supply chain disruptions and other impacts on the business, or on the Company’s ability to execute business continuity plans, due to from the COVID-19 pandemic, economic factors, such as fluctuations in interest rates and currency exchange rates; competition, including technological advances, new products and patents obtained by competitors; challenges inherent in the research and development of new products, including the uncertainty of clinical success and obtaining regulatory approvals; the uncertainty of the commercial success of new and existing products; patent challenges; the impact of patent expirations; the Company’s ability to successfully execute its strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety issues resulting in product recalls or regulatory action; material adverse litigation or government action, including related to product liability claims; changes in applicable laws and regulations, including tax laws and global healthcare reforms; trends towards containing health care costs; changes in the behavior and spending patterns of buyers of health care products and services; the financial instability of economies and international legal systems and sovereign risk; increased oversight of the health care sector by government agencies. A list and additional descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s annual report on Form 10-K for the year ended January 3, 2021, including in the sections entitled “Disclaimer” regarding forward-looking statements â. and âPoint 1A. Risk Factors âin the Company’s latest Quarterly Report on Form 10-Q and subsequent Company filings with the Securities and Exchange Commission. Copies of these documents are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statements made in this press release speak only as of the date of this press release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
View original content to download multimedia: https://www.prnewswire.com/news-releases/johnson–johnson-announces-jessica-moore-as-vice-president-of-investor-relations-301398394.html
SOURCE Johnson & Johnson